Misplaced Pages

Richard Barker (businessman): Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 15:51, 17 December 2021 editBusbel (talk | contribs)Extended confirmed users5,368 editsNo edit summaryTag: Visual edit← Previous edit Latest revision as of 18:16, 9 October 2024 edit undoWikiCleanerBot (talk | contribs)Bots925,164 editsm v2.05b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation)Tag: WPCleaner 
(39 intermediate revisions by 26 users not shown)
Line 1: Line 1:
{{Short description|British healthcare consultant}}

{{Multiple issues|
{{Advert|date=July 2020}} {{Advert|date=July 2020}}
{{Autobiography|date=August 2024}}
'''Richard William Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is a British life sciences and healthcare leader, board member, advisor, ] and author. He is known as the Founder of New Medicine Partners and Founding Director of the University of Oxford — University College of London ] (CASMI).<ref name=CASMI>{{cite web|title=Dr Richard Barker OBE|url=http://casmi.org.uk/dr-richard-barker/|publisher=CASMI|accessdate=2013-02-11|url-status=dead|archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/|archivedate=2013-04-23}}</ref>
}}
'''Prof. Richard Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is a healthcare leader who has contributed to the field through his forward-thinking approach and innovative work. He co-founded and chairs Metadvice,<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-26}}</ref> a company developing AI-driven healthcare platforms. He also established New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-26}}</ref> and is the Founding Director of the ]'s ], now called the Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), which is hosted by University College London and focuses on translating bioscience into medical treatments.<ref name="CASMI">{{cite web |title=Dr Richard Barker OBE |url=http://casmi.org.uk/dr-richard-barker/ |url-status=dead |archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/ |archivedate=2013-04-23 |accessdate=2024-08-26 |publisher=CASMI}}</ref> Barker is the chair of the advisory board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-26}}</ref> and a co-founder and board member of 2BWell,<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-26}}</ref> a mental health initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at ].


{{Infobox person {{Infobox person
| name = Richard William Barker | name = Richard William Barker
| occupation = life sciences and healthcare leader | occupation = Life Sciences and Healthcare leader
| known_for = | known_for = Founder of New Medicine Partners and Founding Director of the University of Oxford.
}} }}


== Early life == == Early life ==
Barker was born in South London. He attended Alleyn's School<ref>{{Cite web|title=Home - Alleyn's School|url=https://www.alleyns.org.uk/|access-date=2021-10-05|website=www.alleyns.org.uk|language=en-US}}</ref> in Dulwich, London, until the age of 18. Barker was born in South London and attended ] in ].
Family relatives include Joan Barker, Arthur Barker, Clifford Barker, Kia Barker.


== Higher education == == Education ==
Barker was educated at Exeter College, Oxford,<ref>{{Cite web|title=Homepage|url=http://www.exeter.ox.ac.uk/|access-date=2021-10-05|website=Exeter College|language=en-GB}}</ref> where he received a ] in chemistry. Following completion of his degree, he researched biological applications of ]s in pursuit of an Oxford<ref>{{Cite web|title=University of Oxford|url=https://www.ox.ac.uk/|access-date=2021-10-05|website=www.ox.ac.uk}}</ref> ] degree, followed by post-doctoral studies in ], Germany and ].<ref>{{Cite web|url=http://www.hm.edu/en/|title=Munich University MUAS - HM Hochschule München University of Applied Sciences}}</ref><ref>{{Cite web|last=Leeds|first=University of|title=University of Leeds|url=https://www.leeds.ac.uk/|access-date=2021-10-05|website=www.leeds.ac.uk|language=en}}</ref> Barker was educated at ], where he received a ] in chemistry. He pursued research on the biological applications of ] techniques for his ] in Philosophy at ], followed by ] studies in ], ], and ].


==Career== ==Career==
Barker's business career has included work in both Europe and the US.<ref name=Bloomberg>{{cite web|title=Richard W. Barker D.Phil., B.A., M.A.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=436430&ticker=ICO:CN&previousCapId=23112550&previousTitle=ICO%20THERAPEUTICS%20INC|publisher=Investing.businessweek.com|accessdate=2013-02-11}}</ref> He worked for ]<ref>{{Cite web|title=McKinsey & Company {{!}} Global management consulting|url=https://www.mckinsey.com/|access-date=2021-10-05|website=www.mckinsey.com|language=en}}</ref> between 1980 and 1993, where he headed the European Healthcare practice<ref>http://www.mckinsey.com/client_service/healthcare_systems_and_services<nowiki/>{{Dead link|date=October 2021}}</ref> and advised UK, Swiss and US pharmaceutical companies. He also helped establish 'London First',<ref>{{Cite web|title=London First|url=https://www.londonfirst.co.uk/|access-date=2021-10-05|website=www.londonfirst.co.uk}}</ref> a public/private initiative that aims to enhance London's status as a global city. As General Manager of ]'s healthcare business,<ref>{{Cite web|url=http://www-935.ibm.com/industries/uk/en/healthcare/|title=Healthcare Technology Solutions & Services}}</ref> between 1993 and 1996 he launched Healthvillage, one of the earliest Internet healthcare applications.<ref></ref> At ],<ref>{{Cite web|url=http://www.nndb.com/company/216/000123844/|title=Chiron Corporation}}</ref> a multinational biotechnology firm that was acquired by ] in 1996, he headed the diagnostics business, which brought the latest ] to market.<ref>{{Cite web|url=http://www.chemeurope.com/en/encyclopedia/Chiron_Corporation.html|title = Chiron_Corporation}}</ref> He subsequently served as chairman and chief executive of Molecular Staging,<ref>http://molecularstaging.aussieblogs.com.au<nowiki/>{{Dead link|date=December 2021}}</ref> whose genome amplification technology enables gene sequencing on rare DNA samples.<ref>http://molecularstaging.aussieblogs.com.au/technology/<nowiki/>{{Dead link|date=December 2021}}</ref> Barker's business career has included work in both Europe and the US.<ref name=Bloomberg>{{cite web|title=Richard W. Barker D.Phil., B.A., M.A.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=436430&ticker=ICO:CN&previousCapId=23112550&previousTitle=ICO%20THERAPEUTICS%20INC|publisher=Investing.businessweek.com|accessdate=2013-02-11}}{{dead link|date=April 2023|bot=medic}}{{cbignore|bot=medic}}</ref> He worked for ]<ref>{{Cite web|title=McKinsey & Company {{!}} Global management consulting|url=https://www.mckinsey.com/|access-date=2021-10-05|website=www.mckinsey.com|language=en}}</ref> between 1980 and 1993, where he headed the European Healthcare practice<ref>http://www.mckinsey.com/client_service/healthcare_systems_and_services {{Webarchive|url=https://web.archive.org/web/20130424150911/http://www.mckinsey.com/client_service/healthcare_systems_and_services |date=2013-04-24 }}</ref> and advised UK, Swiss and US pharmaceutical companies. He also helped establish ']',<ref>{{Cite web|title=London First|url=https://www.londonfirst.co.uk/|access-date=2021-10-05|website=www.londonfirst.co.uk}}</ref> a public/private initiative that aims to enhance London's status as a global city. As General Manager of ]'s healthcare business,<ref>{{Cite web|url=http://www-935.ibm.com/industries/uk/en/healthcare/|title=Healthcare Technology Solutions & Services}}</ref> between 1993 and 1996 he launched ], one of the earliest Internet healthcare applications.<ref></ref> At ],<ref>{{Cite web|url=http://www.nndb.com/company/216/000123844/|title=Chiron Corporation}}</ref> a multinational bio-technology firm that was acquired by ] in 1996, he headed the diagnostics business, which brought the latest ] to market.{{cn|date=May 2022}} He subsequently served as a chairman and chief executive of Molecular Staging,<ref>http://molecularstaging.aussieblogs.com.au {{Webarchive|url=https://web.archive.org/web/20130420114935/http://molecularstaging.aussieblogs.com.au/ |date=2013-04-20 }}</ref> whose ] enables ] on rare ].<ref>http://molecularstaging.aussieblogs.com.au/technology/ {{Webarchive|url=https://web.archive.org/web/20140125225325/http://molecularstaging.aussieblogs.com.au/technology/ |date=2014-01-25 }}</ref>


On returning to the UK, he headed the ] (ABPI) for six years between 2004 and 2011<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|date=9 January 2012|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher=Pmlive.com|accessdate=2013-02-11}}</ref> and initiated policy programmes in stratified medicine,<ref>try-info/future/Pages/personalised-medicines.aspx</ref> while also launching frameworks for translational partnerships between academia and industry.<ref>http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx<nowiki/>{{Dead link|date=December 2021}}</ref> He also formed and chaired Stem Cells for Safer Medicines,<ref>http://www.sc4sm.org<nowiki/>{{Dead link|date=December 2021}}</ref> a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity. On returning to the UK, he headed the ] (ABPI) for six years between 2004 and 2011<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|date=9 January 2012|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher=Pmlive.com|accessdate=2013-02-11}}</ref> and initiated policy programs in stratified medicine,<ref>try-info/future/Pages/personalised-medicines.aspx</ref> while also launching frameworks for translational partnerships between academia and industry.<ref>http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx {{Webarchive|url=https://web.archive.org/web/20130407085850/http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx |date=2013-04-07 }}</ref> He also formed and chaired Stem Cells for Safer Medicines,<ref>http://www.sc4sm.org {{Webarchive|url=https://web.archive.org/web/20220617163230/https://www.sc4sm.org/ |date=2022-06-17 }}</ref> a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.


In 2012 with his colleagues at Oxford and UCL he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.<ref>http://www.casmi.org.uk<nowiki/>{{Dead link|date=December 2021}}</ref> As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.<ref>{{Cite web|title=UCL School of Life and Medical Sciences — CASMI|date=14 August 2018|url=https://www.ucl.ac.uk/school-life-medical-sciences/research/casmi|url-status=live}}</ref> In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.<ref>http://www.casmi.org.uk {{Webarchive|url=https://web.archive.org/web/20180625202006/http://casmi.org.uk/ |date=2018-06-25 }}</ref> As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.<ref>{{Cite web|title=UCL School of Life and Medical Sciences — CASMI|date=14 August 2018|url=https://www.ucl.ac.uk/school-life-medical-sciences/research/casmi}}</ref>


He chairs the South London Academic Health Science Network,<ref>{{Cite web|url=http://www.kingshealthpartners.org/info/southlondonahsn|title = About Us &#124; King's Health Partners &#124; London}}</ref> which aims to improve the quality and consistency of care in that part of the ] (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.<ref>{{Cite web|url=https://www.gov.uk/government/publications/academic-health-science-networks-request-for-expressions-of-interest-to-create-ahsns--2|title = &#91;Withdrawn&#93; Academic health science networks: Request for expressions of interest to create AHSNs}}</ref> He chairs the South London Academic Health Science Network,<ref>{{Cite web|url=http://www.kingshealthpartners.org/info/southlondonahsn|title = About Us &#124; King's Health Partners &#124; London}}</ref> which aims to improve the quality and consistency of care in that part of the ] (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.<ref>{{Cite web|url=https://www.gov.uk/government/publications/academic-health-science-networks-request-for-expressions-of-interest-to-create-ahsns--2|title = &#91;Withdrawn&#93; Academic health science networks: Request for expressions of interest to create AHSNs| date=15 September 2014 }}</ref>


Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters. <ref>{{Cite web|title=CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|url=https://www.sec.gov/Archives/edgar/data/0001690080/000121390020044354/ea132067-8k_180lifescien.htm|url-status=live|access-date=2021-12-16}}</ref> Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters. <ref>{{Cite web|title=CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|url=https://www.sec.gov/Archives/edgar/data/0001690080/000121390020044354/ea132067-8k_180lifescien.htm|access-date=2021-12-16}}</ref>


He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.<ref>{{Cite web|url=http://www.ihpuk.org/our-team/4594052457|title=ABOUT - IHP|website=www.ihpuk.org|language=en|access-date=2018-06-10}}</ref> He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.<ref>{{Cite web|url=http://www.ihpuk.org/our-team/4594052457|title=ABOUT - IHP|website=www.ihpuk.org|language=en|access-date=2018-06-10}}</ref>


He has also founded and directs New Medicine Partners, an advisory company that creates strategy for precision medicine and precision health to advance healthy lifespan.<ref>{{Cite web|url=https://www.newmedicine.io|title=Welcome to New Medicine Partners|website=New Medicine Partners|language=en-GB|access-date=2018-06-10}}</ref> He is also Founding Director of Metadvice, a global healthcare company developing an AI-driven platform for clinical decision making.<ref>{{Cite web|title=Metadvice :: Team {{!}} Leaders {{!}} Experts|url=https://www.metadvice.com/team3.php|access-date=2021-04-07|website=www.metadvice.com}}</ref> He has also founded and directed New Medicine Partners, an advisory company that creates strategies for precision medicine and precision health to advance a healthy lifespan.<ref>{{Cite web|url=https://www.newmedicine.io|title=Welcome to New Medicine Partners|website=New Medicine Partners|language=en-GB|access-date=2018-06-10}}</ref> He is also the Founding Director of ], a global healthcare company developing an AI-driven platform for clinical decision making.<ref>{{Cite web|title=Metadvice :: Team {{!}} Leaders {{!}} Experts|url=https://www.metadvice.com/team3.php|access-date=2021-04-07|website=www.metadvice.com}}</ref>


== Board memberships == == Board memberships ==
* ]<ref>{{cite web|url=http://www.innovationdebate.com/debate/panelists/dr-richard-barker/ |title=Dr Richard W. Barker: The Innovation Debate 2012 |publisher=Innovationdebate.com |date=2012-11-20 |accessdate=2013-02-19}}</ref> * ]<ref>{{cite web|url=http://www.innovationdebate.com/debate/panelists/dr-richard-barker/ |title=Dr Richard W. Barker: The Innovation Debate 2012 |publisher=Innovationdebate.com |date=2012-11-20 |accessdate=2013-02-19}}</ref>
*<ref>{{Cite web|url=http://www.ia-grp.com/experts/richard-barker-obe/|title=Richard Barker, OBE {{!}} IAG|website=www.ia-grp.com|language=en-US|access-date=2018-06-10}}</ref>
*


== Awards == == Awards ==

Latest revision as of 18:16, 9 October 2024

British healthcare consultant
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (July 2020) (Learn how and when to remove this message)
This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. It may need editing to conform to Misplaced Pages's neutral point of view policy. There may be relevant discussion on the talk page. (August 2024) (Learn how and when to remove this message)
(Learn how and when to remove this message)

Prof. Richard Barker OBE FFPM is a healthcare leader who has contributed to the field through his forward-thinking approach and innovative work. He co-founded and chairs Metadvice, a company developing AI-driven healthcare platforms. He also established New Medicine Partners and is the Founding Director of the University of Oxford's Centre for the Advancement of Sustainable Medical Innovation, now called the Collaboration for the Advancement of Sustainable Medical Innovation (CASMI), which is hosted by University College London and focuses on translating bioscience into medical treatments. Barker is the chair of the advisory board at NWPharmaTech and a co-founder and board member of 2BWell, a mental health initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at King’s College London.

Richard William Barker
Occupation(s)Life Sciences and Healthcare leader
Known forFounder of New Medicine Partners and Founding Director of the University of Oxford.

Early life

Barker was born in South London and attended Alleyn's School in Dulwich, London.

Education

Barker was educated at Exeter College, Oxford, where he received a bachelor's degree in chemistry. He pursued research on the biological applications of magnetic resonance techniques for his PhD in Philosophy at Oxford University, followed by post-doctoral studies in Munich, Germany, and Leeds, England.

Career

Barker's business career has included work in both Europe and the US. He worked for McKinsey between 1980 and 1993, where he headed the European Healthcare practice and advised UK, Swiss and US pharmaceutical companies. He also helped establish 'London First', a public/private initiative that aims to enhance London's status as a global city. As General Manager of IBM's healthcare business, between 1993 and 1996 he launched Health village, one of the earliest Internet healthcare applications. At Chiron, a multinational bio-technology firm that was acquired by Novartis in 1996, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as a chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.

On returning to the UK, he headed the Association of the British Pharmaceutical Industry (ABPI) for six years between 2004 and 2011 and initiated policy programs in stratified medicine, while also launching frameworks for translational partnerships between academia and industry. He also formed and chaired Stem Cells for Safer Medicines, a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.

In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit. As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.

He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the National Health Service (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.

Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters.

He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.

He has also founded and directed New Medicine Partners, an advisory company that creates strategies for precision medicine and precision health to advance a healthy lifespan. He is also the Founding Director of Metadvice, a global healthcare company developing an AI-driven platform for clinical decision making.

Board memberships

Awards

In 2011 Professor Richard Barker was awarded the Order of the British Empire for his services to the pharmaceutical industry by the Queen Elizabeth II. In 2021 he was awarded Honorary Fellowship of the Faculty of Pharmaceutical Medicine.

Published works

Books
  • Barker, Richard (2010). 2030: the Future of Medicine, Oxford University Press, 118 pages. ISBN 978-0199600663
  • Barker, Richard (2016). Bioscience — Lost in Translation?, Oxford University Press, 226 pages. ISBN 978-0198737780
Selected Articles
  • Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", Regulatory Rapporteur, Vol 9, No 10, page 13, October 2012.
  • Barker, Richard. "A flexible blueprint for the future of drug development", The Lancet, Volume 375, Issue 9712, pages 357–359, 30 January 2010.
  • See CASMI website.

References

  1. "Metadvice". Retrieved 2024-08-26.
  2. "New Medicine Partners". Retrieved 2024-08-26.
  3. "Dr Richard Barker OBE". CASMI. Archived from the original on 2013-04-23. Retrieved 2024-08-26.
  4. "NWPharmaTech". Retrieved 2024-08-26.
  5. "2BWell". Retrieved 2024-08-26.
  6. "Richard W. Barker D.Phil., B.A., M.A." Investing.businessweek.com. Retrieved 2013-02-11.
  7. "McKinsey & Company | Global management consulting". www.mckinsey.com. Retrieved 2021-10-05.
  8. http://www.mckinsey.com/client_service/healthcare_systems_and_services Archived 2013-04-24 at the Wayback Machine
  9. "London First". www.londonfirst.co.uk. Retrieved 2021-10-05.
  10. "Healthcare Technology Solutions & Services".
  11. EBSCOhost Connection
  12. "Chiron Corporation".
  13. http://molecularstaging.aussieblogs.com.au Archived 2013-04-20 at the Wayback Machine
  14. http://molecularstaging.aussieblogs.com.au/technology/ Archived 2014-01-25 at the Wayback Machine
  15. "Former ABPI head Richard Barker joins Aegate as senior adviser". Pmlive.com. 9 January 2012. Retrieved 2013-02-11.
  16. try-info/future/Pages/personalised-medicines.aspx
  17. http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx Archived 2013-04-07 at the Wayback Machine
  18. http://www.sc4sm.org Archived 2022-06-17 at the Wayback Machine
  19. http://www.casmi.org.uk Archived 2018-06-25 at the Wayback Machine
  20. "UCL School of Life and Medical Sciences — CASMI". 14 August 2018.
  21. "About Us | King's Health Partners | London".
  22. "[Withdrawn] Academic health science networks: Request for expressions of interest to create AHSNs". 15 September 2014.
  23. "CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934". Retrieved 2021-12-16.
  24. "ABOUT - IHP". www.ihpuk.org. Retrieved 2018-06-10.
  25. "Welcome to New Medicine Partners". New Medicine Partners. Retrieved 2018-06-10.
  26. "Metadvice :: Team | Leaders | Experts". www.metadvice.com. Retrieved 2021-04-07.
  27. "Dr Richard W. Barker: The Innovation Debate 2012". Innovationdebate.com. 2012-11-20. Retrieved 2013-02-19.
  28. "Honours: Order of the British Empire, Civil - OBE". The Independent. 2011-12-30. Retrieved 2021-04-07.
Categories: